Liver cirrhosis
Conditions
Interventions
Treatment group:Umbilical cord blood stem cells
Control group:0.9% Sodium chloride containing 1% Human Albumin
Sponsors
Taihe Hospital, Hubei University of Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. A history of chronic HBV infection; 2. Ultrasonographic evidence of LC; 3. HBV DNA >100 IU/ ml; 4. CTP Score more than 7.
Exclusion criteria
Exclusion criteria: 1. The presence of HCC and any underlying neoplasm; 2. Liver failure (TBil>10 ULN, PTA<40%); 3. A history of variceal bleeding 2 months prior to the enrolment; 4. The presence of severe comorbidities; 5. Coinfection with HAV, HCV, HDV, HEV, HIV, etc; 6. Evidence of extrahepatic biliary diseases; 7. The presence of hepatic, portal, or splenic vein thromboses on Doppler ultrasonography; 8. Active substance abuse; 9. A history of nucleot(s)ides administration 6 months prior to the enrolment; 10. Unwillingness to sign the informed consent form.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Liver function;liver stiffnes; | — |
Secondary
| Measure | Time frame |
|---|---|
| HBV DNA; | — |
Countries
China
Contacts
Public ContactZhongji Meng
Taihe Hospital, Hubei University of Medicine
Outcome results
None listed